CASE STUDY Pulmonary Arterial Hypertension in Eastern Europe Case Study Study Overview: Pharm-Olam was selected to provide development services for a Phase III study, which was designed to address the efficacy and safety of a compound for pulmonary arterial hypertension patients. This study originally required 670 patients across the globe, but the enrollment was later increased to 1,150 due to study design changes. Pharm-Olam played an integral part in the enrollment of the additional patients, providing 45% more patients than originally tasked. Pharm-Olam was responsible for: • Recruiting 192 patients, 45% more than the originally requested amount • Management of 17 sites located in Russia, Belarus, and Ukraine • Provided regulatory, project management and

Join for free to read